Treatment of advanced biliary tract cancers: from chemotherapy to targeted agents

Abstract

Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage and have a dismal prognosis. The treatment of advanced disease is mainly based on systemic chemotherapy, which is demonstrated to improve survival in the first- and second-line setting. Following the results of phase III clinical trials, the combination of cisplatin and gemcitabine is the regimen of choice in the frontline, while 5-fluorouracil plus oxaliplatin is considered the standard after first-line progression in unselected patients. Recent advances in molecular biology have unravelled the molecular heterogeneity of BTCs and identified patient subgroups harbouring unique molecular aberrations such as isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted by specific agents. This knowledge has opened the way to personalised medicine in BTCs. Molecules targeting IDH and FGFR are currently approved for the treatment of advanced, refractory, intrahepatic cholangiocarcinoma. Beyond targeted therapies, novel combinatorial approaches that target the immune microenvironment and the crosstalk between cancer and stroma are being explored based on strong preclinical rationale. This review discusses the current therapeutic opportunities for the management of patients with advanced BTCs and provides an overview of the promising new strategies on the horizon with a particular focus on ongoing clinical trials.

Keywords

Biliary tract cancers / cholangiocarcinoma / precision medicine / targeted therapies / fibroblast growth factor receptor / isocitrate dehydrogenase / chemotherapy

References

[1] Valle JW,Khan SA,Gruenberger T.ESMO Guidelines CommitteeBiliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2016;27:v28-37

[2] Valle JW,Nervi B,Zhu AX.Biliary tract cancer.Lancet2021;397:428-44

[3] Spolverato G,Ejaz A.Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients.JAMA Surg2015;150:538-45

[4] Hyder O,Sotiropoulos GC.Recurrence after operative management of intrahepatic cholangiocarcinoma.Surgery2013;153:811-8 PMCID:PMC3980567

[5] Spolverato G,Kim Y.The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma.Ann Surg Oncol2015;22:4020-8

[6] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[7] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[8] Lamarca A,Wasan HS.Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.Lancet Oncol2021;22:690-701 PMCID:PMC8082275

[9] Javle MM,Clarke SJ.Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.J Clin Oncol2019;37:TPS4155

[10] Abou-alfa GK,Javle MM.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020;21:796-807 PMCID:PMC7523268

[11] Lamarca A,McNamara MG.Molecular targeted therapies: Ready for “prime time” in biliary tract cancer.J Hepatol2020;73:170-85

[12] Marin JJG,Lamarca A.working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA)Current and novel therapeutic opportunities for systemic therapy in biliary cancer.Br J Cancer2020;123:1047-59 PMCID:PMC7525457

[13] Shroff RT,Xiao L.Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial.JAMA Oncol2019;5:824-30 PMCID:PMC6567834

[14] Yoo C,Kim I.Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).J Clin Oncol2021;39:4006-4006

[15] Gruenberger B,Heubrandtner U.Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Lancet Oncol2010;11:1142-8

[16] Chen JS,Chiang NJ.Taiwan Cooperative Oncology GroupA KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.Ann Oncol2015;26:943-9

[17] Peck J,Zalupski M,Villalona Calero M.HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.Oncology2012;82:175-9

[18] Ahn DH,Wei L.Results of an abbreviated phase-II study with the akt inhibitor MK-2206 in patients with advanced biliary cancer.Sci Rep2015;5:12122 PMCID:PMC4894406

[19] Bridgewater J,Beare S.A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.BMC Cancer2016;16:153 PMCID:PMC4766710

[20] Goyal L,Abrams TA.A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma.J Clin Oncol2015;33:800-800

[21] Lee J,Chang H.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.Lancet Oncol2012;13:181-8

[22] Malka D,Foulon S.Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Lancet Oncol2014;15:819-28 PMCID:PMC6372099

[23] Zhu AX,Blaszkowsky LS.Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.Lancet Oncol2010;11:48-54

[24] Demols A,Van den Eynde M.Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.Ann Oncol2020;31:1169-77

[25] Valle JW,Johnson P.Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.Br J Cancer2009;101:621-7 PMCID:PMC2736816

[26] Okusaka T,Fukutomi A.Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.Br J Cancer2010;103:469-74 PMCID:PMC2939781

[27] Valle JW,Jitlal M.Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.Ann Oncol2014;25:391-8

[28] Sasaki T,Nakai Y.Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.Cancer Chemother Pharmacol2010;65:1101-7

[29] Schinzari G,Mambella G.First-line treatment of advanced biliary ducts carcinoma: a randomized phase II study evaluating 5-FU/LV plus oxaliplatin (Folfox 4) versus 5-FU/LV (de Gramont Regimen).Anticancer Res2017;37:5193-7

[30] Morizane C,Mizusawa J.members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.Ann Oncol2019;30:1950-8

[31] Sakai D,Kobayashi S.Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA).Ann Oncol2018;29:viii205

[32] Tella SH,Borad MJ.Second-line therapies in advanced biliary tract cancers.Lancet Oncol2020;21:e29-41

[33] Lamarca A,David Ryder W.Second-line chemotherapy in advanced biliary cancer: a systematic review.Ann Oncol2014;25:2328-38

[34] Belkouz A,Mathôt RAA.Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.Br J Cancer2020;122:634-9 PMCID:PMC7054309

[35] Bridgewater J,Cunningham D.Outcome of second-line chemotherapy for biliary tract cancer.Eur J Cancer2013;49:1511

[36] Leone F,Palloni A.Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis.Ann Oncol2017;28:vi48

[37] Brieau B,De Rycke Y.Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues.Cancer2015;121:3290-7

[38] Schweitzer N,Kratzel AM.Second-line chemotherapy in biliary tract cancer: outcome and prognostic factors.Liver Int2019;39:914-23

[39] Takahara N,Isayama H.Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.Invest New Drugs2018;36:1093-102

[40] Lamarca A,Wasan HS.Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials.J Natl Cancer Inst2020;112:200-10

[41] Salati M,Vivaldi C.The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer.Liver Int2020;40:704-11

[42] Filippi R,Fornaro L.Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.J Chemother2021;:1-10

[43] Filippi R,Lombardi P.A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.Acta Oncol2021;60:1317-24

[44] Casadei-Gardini A,Rimini M.Effects of metformin and vitamin D on clinical outcome in cholangiocarcinoma patients.Oncology2021;99:292-9

[45] Rovesti G,Brandi G.Prognostic role of a new index tested in European and Korean advanced biliary tract cancer patients: the PECS index.J Gastrointest Cancer2021;

[46] Jusakul A,Yong CH.Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma.Cancer Discov2017;7:1116-35 PMCID:PMC5628134

[47] Lowery MA,Jordan E.Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention.Clin Cancer Res2018;24:4154-61 PMCID:PMC6642361

[48] Chan-On W,Ong CK.Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.Nat Genet2013;45:1474-8

[49] Welcome to the Pan-Cancer Atlas. Available from: https://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html [Last accessed on 16 Nov 2021]

[50] Ong CK,Pairojkul C.Exome sequencing of liver fluke-associated cholangiocarcinoma.Nat Genet2012;44:690-3

[51] Li M,Li X.Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.Nat Genet2014;46:872-6

[52] Narayan RR,Goldman DA.Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.Cancer2019;125:575-85 PMCID:PMC6636637

[53] Zou S,Zhou H.Mutational landscape of intrahepatic cholangiocarcinoma.Nat Commun2014;5:5696

[54] Jiao Y,Anders RA.Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.Nat Genet2013;45:1470-3 PMCID:PMC4013720

[55] Bogenberger JM,Arora M,Borad MJ.Emerging role of precision medicine in biliary tract cancers.NPJ Precis Oncol2018;2:21 PMCID:PMC6170410

[56] Wardell CP,Yamada T.Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.J Hepatol2018;68:959-69

[57] Nakamura H,Totoki Y.Genomic spectra of biliary tract cancer.Nat Genet2015;47:1003-10

[58] Chaisaingmongkol J,Dang H.TIGER-LC ConsortiumCommon molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma.Cancer Cell2017;32:57-70.e3 PMCID:PMC5524207

[59] cBioPortal for Cancer Genomics. Available from: https://www.cbioportal.org/study/summary?id=chol_nccs_2013 [Last accessed on 16 Nov 2021]

[60] Arai Y,Hosoda F.Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.Hepatology2014;59:1427-34

[61] Graham RP,Pestova E.Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.Hum Pathol2014;45:1630-8

[62] Ross JS,Gay L.New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.Oncologist2014;19:235-42 PMCID:PMC3958461

[63] Sia D,Moeini A.Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.Nat Commun2015;6:6087

[64] Voss JS,Kerr SE.Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.Hum Pathol2013;44:1216-22

[65] Wu YM,Kalyana-Sundaram S.Identification of targetable FGFR gene fusions in diverse cancers.Cancer Discov2013;3:636-47 PMCID:PMC3694764

[66] Borad MJ,Egan JB.Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.PLoS Genet2014;10:e1004135 PMCID:PMC3923676

[67] Putra J,Peterson JD.Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.Exp Mol Pathol2015;99:240-4 PMCID:PMC4591249

[68] Zhu AX,Kim Y.Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Ann Surg Oncol2014;21:3827-34 PMCID:PMC4324507

[69] Sia D,Villanueva A.Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.Gastroenterology2013;144:829-40 PMCID:PMC3624083

[70] Farshidfar F,Gingras MC.Cancer Genome Atlas NetworkIntegrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles.Cell Rep2017;18:2780-94 PMCID:PMC5493145

[71] Nepal C,Oliveira DVNP.Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.Hepatology2018;68:949-63 PMCID:PMC6599967

[72] Job S,Dos Santos A.Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma.Hepatology2020;72:965-81 PMCID:PMC7589418

[73] Verlingue L,Allorant A.Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.Eur J Cancer2017;87:122-30

[74] Lowery MA,Burris HA.Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts.J Clin Oncol2017;35:4015-4015

[75] Zhu AX,Javle MM.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial.JAMA Oncol2021; PMCID:PMC8461552

[76] FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma [Last accessed on 16 Nov 2021]

[77] Javle M,Shroff RT.Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.J Clin Oncol2018;36:276-82 PMCID:PMC6075847

[78] Mazzaferro V,Droz Dit Busset M.Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.Br J Cancer2019;120:165-71 PMCID:PMC6342954

[79] Vogel A,Hollebecque A.FIGHT-202: a phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA).Ann Oncol2019;30:v876

[80] Jain A,Kelley RK.Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype.JCO Precision Oncology2018;

[81] Javle MM,El-khoueiry AB.A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.J Clin Oncol2020;38:4591

[82] Abou-alfa GK,Hollebecque A.Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): update of FIGHT-202.J Clin Oncol2021;39:4086

[83] Goyal L,Liu LY.Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma.Cancer Discov2017;7:252-63 PMCID:PMC5433349

[84] Goyal L,Liu LY.TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.Cancer Discov2019;9:1064-79 PMCID:PMC6677584

[85] Silverman IM,Lihou CF.Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.J Clin Oncol2019;37:4080

[86] Cocco E,Kulick A.Resistance to TRK inhibition mediated by convergent MAPK pathway activation.Nat Med2019;25:1422-7 PMCID:PMC6736691

[87] Misale S,Tong J.Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.Nat Commun2015;6:8305 PMCID:PMC4595628

[88] Park JJH,Siden EG,Mills EJ.An overview of precision oncology basket and umbrella trials for clinicians.CA Cancer J Clin2020;70:125-37 PMCID:PMC7187272

[89] Hyman DM,Subbiah V.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations.N Engl J Med2015;373:726-36 PMCID:PMC4971773

[90] Subbiah V,Élez E.Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Lancet Oncol2020;21:1234-43

[91] Hainsworth JD,Swanton C.Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study.J Clin Oncol2018;36:536-42

[92] Robert C.A decade of immune-checkpoint inhibitors in cancer therapy.Nat Commun2020;11:3801 PMCID:PMC7393098

[93] Kim RD,Alese OB.A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer.JAMA Oncol2020;6:888-94 PMCID:PMC7193528

[94] Shen T,Geng L.Experience with anti-PD-1 antibody, camrelizumab, monotherapy for biliary tract cancer patients and literature review.Technol Cancer Res Treat2020;19:1533033820979703 PMCID:PMC7739105

[95] Marcus L,Keegan P.FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors.Clin Cancer Res2019;25:3753-8

[96] Piha-Paul SA,Ueno M.Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies.Int J Cancer2020;147:2190-8

[97] Gani F,Kim Y.Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma.Ann Surg Oncol2016;23:2610-7

[98] Kitano Y,Nakao Y.Clinical significance of PD-L1 expression in both cancer and stroma cells of cholangiocarcinoma patients.Ann Surg Oncol2020;27:599-607

[99] Pinato DJ,Fessas P.Immune-based therapies for hepatocellular carcinoma.Oncogene2020;39:3620-37 PMCID:PMC7190571

[100] Marabelle A,Ascierto PA.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.J Clin Oncol2020;38:1-10 PMCID:PMC8184060

[101] Ueno M,Morizane C.Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.Lancet Gastroenterol Hepatol2019;4:611-21

[102] Merck reports topline data for Bintrafusp alfa as second-line monotherapy treatment in biliary tract cancer. Available from: https://www.merckgroup.com/en/news/bintrafusp-topline-data-biliary-tract-cancer-16-03-2021.html [Last accessed on 16 Nov 2021]

[103] Merck statement on phase II study of Bintrafusp alfa in first-line treatment of biliary tract cancer. Available from: https://www.merckgroup.com/en/news/bintrafusp-alfa-update-23-08-2021.html [Last accessed on 16 Nov 2021]

[104] Arkenau HT,Calvo E.Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF).Oncologist2018;23:1407-e136 PMCID:PMC6292555

[105] Sulpice L,Desille M.Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma.Hepatology2013;58:1992-2000

[106] Sulpice L,Turlin B.Gene expression profiling of the tumor microenvironment in human intrahepatic cholangiocarcinoma.Genom Data2016;7:229-32 PMCID:PMC4778675

[107] Louis C,Coulouarn C.Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.Expert Opin Ther Targets2021;25:153-62

[108] Brivio S,Strazzabosco M.Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness.World J Hepatol2017;9:455-68 PMCID:PMC5368623

[109] Martín-Sierra C,Laranjeira P.Functional and phenotypic characterization of tumor-infiltrating leukocyte subsets and their contribution to the pathogenesis of hepatocellular carcinoma and cholangiocarcinoma.Transl Oncol2019;12:1468-79 PMCID:PMC6712279

[110] Sirica AE.Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting.Hepatology2014;59:2397-402 PMCID:PMC3975806

[111] Zhou G,Mancham S.Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.J Hepatol2019;71:753-62

[112] Chen Z,Xie X,Wang Y.The role of tumour microenvironment: a new vision for cholangiocarcinoma.J Cell Mol Med2019;23:59-69 PMCID:PMC6307844

[113] Raggi C,Sica A.Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.J Hepatol2017;66:102-15 PMCID:PMC5522599

[114] Mertens JC,Christensen JD.Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.Cancer Res2013;73:897-907 PMCID:PMC3549008

[115] Ling H,Hempel D.Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats.PLoS One2013;8:e54499 PMCID:PMC3547926

[116] Mehta R,Yu J.Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.Expert Opin Investig Drugs2021;30:451-61

[117] Ahn DH.Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.Chin Clin Oncol2020;9:6

[118] O'Connor MJ.Targeting the DNA damage response in cancer.Mol Cell2015;60:547-60

[119] Golan T,Kelley RK.Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study.Oncologist2017;22:804-10 PMCID:PMC5507643

[120] Sulkowski PL,Robinson ND.2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Sci Transl Med2017;9:eaal2463 PMCID:PMC5435119

[121] Peyraud F.Combined PARP inhibition and immune checkpoint therapy in solid tumors.Cancers (Basel)2020;12:1502 PMCID:PMC7352466

[122] Miyamoto M,Iwasaki M.Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.Br J Cancer2011;105:131-8 PMCID:PMC3137414

[123] Lyseng-Williamson KA.Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use.Drugs Ther Perspect2018;34:457-65 PMCID:PMC6323107

[124] Goyal L,Yurgelun MB.A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.Cancer2017;123:1979-88 PMCID:PMC5444988

[125] Zuo M,Churi C.Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.Br J Cancer2015;112:1042-51 PMCID:PMC4366884

[126] Corti F,Raimondi A.Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives.Cancer Treat Rev2019;72:45-55

[127] Goeppert B,Schmidt CR.Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.Hepatology2014;59:544-54

[128] O'Rourke CJ,Aguayo EL.Epigenome dysregulation in cholangiocarcinoma.Biochim Biophys Acta Mol Basis Dis2018;1864:1423-34